FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
What to do next
Read the issuing agency's notice carefully, compare the product identifiers, and follow the official remedy instructions. RecallDefense helps you keep watch, but the source agency's notice is the authority for action.
Source attribution: FDA. Published Sep 1, 2021.
